Summary
Nafimidone is a new antiepileptic drug which may be effective in partial onset seizures. We studied the pharmacokinetics of nafimidone and its metabolite, nafimidone alcohol, in 12 patients already taking phenytoin and/or carbamazepine. The half life of nafimidone was 1.34 ± 0.48 hours after a 100mg single dose and 1.69 ± 0.91 hours after a 300mg single dose. However, the half-life of nafimidone alcohol increased from 2.84 ± 0.72 hours after a 100mg single dose to 4.22 ± 1.09 hours after a 300mg single dose (p < 0.02). The clearance of nafimidone was 43.56 ± 22.11 L/h/kg after a 100mg single dose and 35.51 ± 28.93 L/h/kg after the 300mg single dose. The respective apparent volumes of distribution of nafimidone after single 100 and 300mg doses were 80.78 ± 46.11 L/kg and 71.01 ± 36.86 L/kg. After short term (9 to 10 weeks) and long term (127 to 152 weeks) maintenance therapy on nafimidone 600mg per day the half-life of nafimidone alcohol was 2.23 ± 0.36 hours and 2.16 ± 0.60 hours, respectively. No nafimidone could be detected in urine but from 4 to 7% of the daily nafimidone dose was recovered as nafimidone alcohol. Thus, it appears that over 90% of the administered dose of nafimidone is metabolised by pathways other than glucuronidation of nafimidone alcohol and urinary excretion.
Similar content being viewed by others
References
Buhles W, Wallach M, Chaplin M, Treiman DM. Nafimidone — a novel imidazole anticonvulsant. In Porter & Meldrum (Eds) Current problems in epilepsy IV, New anticonvulsant drugs pp. 203–214, John Libbey, London, 1986
Fincham RW, Schottelius DD. Primidone: interactions with other drugs. In Woodburry et al. (Eds) Antiepileptic drugs, 2nd ed., pp. 421–429, Raven Press, New York, 1982
Gunawan S, Treiman DM. HPLC determination of nafimidone and its major metabolite, nafimidone alcohol, in human plasma and urine. Journal of Chromatography 414: 389–398, 1987
Lander CM, Eadie MJ, Tyrer JH. Factors influencing plasma carbamazepine concentrations. Clinical and Experimental Neurology 14: 184–93, 1977
Rambeck B. Pharmacological interactions of methsuximide with phenobarbital and phenytoin in hospitalized epileptic patients. Epilepsia 20: 147–56, 1979
Rambeck B, Boenighk HE, Dunlop A, Mullen PW, Wadsworth J, et al. Predicting phenytoin dose: a revised nomogram. Therapeutic Drug Monitoring 1: 325, 1980
Reunanen MI, Luoma P, Myllya VV, Hokkanen E. Low serum valproic acid concentrations in epileptic patients on combination therapy. Current Therapy Research 28: 456–462, 1980
Treiman DM, Ben-Menachem E, Barber KO. Inhibition of carbamazepine and phenytoin elimination by nafimidone, a new antiepileptic drug. Submitted for publication, 1987
Treiman DM, Kupferberg HJ, Ben-Menachem E, Barber KO, Chelberg R, et al. Inhibition of the metabolism of carbamazepine and its metabolites by nafimidone, a new antiepileptic drug. Neurology 35 (Suppl.): 285, 1985a
Treiman DM, Wilensky AJ, Ben-Menachem E, Ojemann L, Yerby M, et al. Efficacy of nafimidone in the treatment of intractable partial seizures: report of a two-center pilot study. Epilepsia 26: 607, 1985b
Warren JW, Benmaman JD, Wannamaker BB, Levy RH. Kinetics of carbamazepine-ethosuximide interaction. Clinical Pharmacology and Therapeutics 28: 646–651, 1980
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Treiman, D.M., Gunawan, S. Pharmacokinetics of Nafimidone in Patients with Chronic Intractable Epilepsy. Clin-Pharmacokinet 12, 433–439 (1987). https://doi.org/10.2165/00003088-198712060-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198712060-00003